News & Events
June 7, 2022
C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease
C-Path and MitoAction today announced a joint collaboration to incorporate patient data for rare mitochondrial disorders into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).
June 2, 2022
xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records
xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with the U.S. Food and Drug Administration (FDA), and the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).
June 2, 2022
Biochemist, Biotechnology Expert to Lead C-Path’s Type 1 Diabetes Consortium
C-Path has named Elnaz Atabakhsh, Ph.D., as Executive Director of its Type 1 Diabetes Consortium (T1DC). Atabakhsh joined C-Path this May with extensive experience in the biotechnology and biomarker development industry. Her previous work focused on biomarker discovery and screening, cancer genetics and cell therapies for autoimmune disorders, aimed at supporting patients unable to be served by traditional therapeutics. Atabakhsh has extensive experience in and a passion for leading patient-oriented, mission-driven collaborations that include diverse representation from the scientific and medical communities.
June 1, 2022
C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database
C-Path has received fully anonymized electronic patient record (EPR) data from the National Neonatal Research Database (NNRD). This is part of efforts to better understand and find treatments for a chronic lung disease which frequently affects premature infants. This initiative, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). It is the first time C-Path has received EPR data from the United Kingdom and includes data from a network of nearly 200 hospitals in England.
May 31, 2022
FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data
The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments to patients affected by facioscapulohumeral muscular dystrophy (FSHD), has partnered with Critical Path Institute (C-Path) to facilitate the integration of clinical trial data from the control arm of various FSHD-related clinical studies into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP ®). These data will come from several companies that have sponsored clinical trials in FSHD.